US2012201818A1PendingUtilityA1

Treatment of multiple sclerosis

59
Assignee: CURD JOHN GPriority: May 7, 1999Filed: Apr 18, 2012Published: Aug 9, 2012
Est. expiryMay 7, 2019(expired)· nominal 20-yr term from priority
Inventors:John G. CurdLori KunkelAntonio J. Grillo-Lopez
A61P 9/00A61P 9/08A61P 9/14A61P 37/02A61P 3/10A61P 37/00A61P 5/14A61P 7/04A61P 43/00A61P 9/10A61P 7/00A61P 9/12A61P 5/00A61P 37/06A61P 7/06A61P 35/00A61P 27/02A61P 25/00A61P 29/00A61P 31/06A61P 21/00A61P 1/04Y10S424/801Y10S424/81A61P 13/02C07K 2317/24A61P 13/12C07K 16/2803C07K 16/2887A61P 19/02A61P 1/00A61K 2039/505A61K 51/1027A61P 11/16A61K 31/56A61K 39/3955A61K 2039/54A61K 45/06A61P 17/04A61P 11/06A61P 21/04A61K 31/365A61K 47/6849A61P 17/06A61P 11/00A61P 17/00A61P 17/02A61K 39/395
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.

Claims

exact text as granted — not AI-modified
1 . A method of treating multiple sclerosis in a human comprising administering to the human a therapeutically effective amount of an antibody which binds to human CD20 and depletes B cells, and wherein the antibody is not conjugated with a cytotoxic agent. 
     
     
         2 - 4 . (canceled) 
     
     
         5 . The method of  claim 1  wherein the antibody comprises rituximab. 
     
     
         6 . The method of  claim 1  comprising administering a dose of substantially less than 375 mg/m 2  of the antibody to the human. 
     
     
         7 . The method of  claim 6  wherein the dose is in the range from about 20 mg/m 2  to about 250 mg/m 2 . 
     
     
         8 . The method of  claim 7  wherein the dose is in the range from about 50 mg/m 2  to about 200 mg/m 2 . 
     
     
         9 . The method of  claim 1  comprising administering an initial dose of the antibody followed by a subsequent dose, wherein the mg/m 2  dose of the antibody in the subsequent dose exceeds the mg/m 2  dose of the antibody in the initial dose. 
     
     
         10 . The method of  claim 1  wherein the antibody is a humanized, chimeric, or human antibody. 
     
     
         11 . The method of  claim 1  wherein the antibody is administered as a dose in the range from about 20 mg/m 2  to about 1000 mg/m 2 . 
     
     
         12 . A method of treating multiple sclerosis in a human comprising administering to the human a therapeutically effective amount of rituximab. 
     
     
         13 . A method of treating multiple sclerosis in a human comprising administering to the human a therapeutically effective amount of an antibody which binds to human CD20 and depletes B cells, and wherein the antibody is administered as a dose in the range from about 20 mg/m 2  to about 250 mg/m 2 . 
     
     
         14 . The method of any one of  claims 1 ,  12  and  13 , wherein the administration of the antibody consists of intravenous administration. 
     
     
         15 . The method of any one of  claims 1 ,  12  and  13 , where the administration of the antibody consists of subcutaneous administration.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.